Alyn Davies
Associate Director, Medicinal Chemistry AstraZeneca
Seminars
Thursday 29th October 2026
Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs)
9:30 am
- Development of highly potent (<500 pM) AURKB PROTACs from legacy target binders
- Modification of PROTACs to allow for conjugation to DACs
- Assessment of what PROTAC physicochemical properties make for good DAC payloads
